Proliferative Lupus Nephritis Treatment With Chloroquine and Hydroxychloroquine

Tanta University

Status

Unknown

Conditions

Chloroquine Retinopathy

Proliferative Nephritis

Treatments

Drug: Chloroquine

Drug: Hydroxychloroquine

Study type

Observational

Funder types

Other

Identifiers

NCT03687905

Fatma

Details and patient eligibility

About

Evaluation the efficacy of chloroquine and hydroxychloroquine in the treatment of proliferative lupus nephritis class III and IV in children and adolescents and evaluate the side effects of both drugs .

Full description

All patients will fulfill the diagnostic criteria of SLE. The diagnosis of systemic lupus erythematosus is based on clinical and laboratory criteria. The criteria set developed by the American College of Rheumatology (ACR) and diagnosed wih lupus nephritis class III and IV .

Inclusion Criteria:

Children and adolescents who fulfill diagnostics criteria of SLE and diagnosed with lupus nephritis class III and IV.
All patients will be received steroids , MMF and Angiotensin Converting Enzyme.

Exclusion Criteria:

Patients diagnosed with lupus nephritis class I,II,V and VI.
Patients received Cyclophosphamide in stead of MMF.

Enrollment

60 estimated patients

Sex

All

Ages

10 to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Children and adolescents who fulfill diagnostics criteria of SLE and diagnosed with lupus nephritis class III and IV.
All patients will be received steroids , MMF and Angiotensin Converting Enzyme.

Exclusion criteria